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A B S T R A C T
ERK and Akt have been shown to regulate cell sensitivity to death-inducing stress by phosphorylating GSK-3β, a
major modulator of the threshold for mitochondrial permeability transition. Here we examined intra-mi-
tochondrial localization of the pro-survival kinases and their regulation by phosphatases. Stepwise trypsin di-
gestion of mitochondria isolated from HEK293 or H9c2 cells was performed, and immunoblotting revealed that
GSK-3β and ERK localized dominantly in the outer membrane (OM), while Akt resided at comparable levels in
OM, the inner membrane (IM) and the matrix. Treatment with IGF-1 increased the protein level of Akt in the
matrix, while ERK and GSK-3β protein levels were increased in OM. Simultaneously, IGF-1 treatment elevated
the level of Thr202/Tyr204-phospho-ERK in IM and matrix and levels of Ser473-phospho-Akt and Ser9-phospho-
GSK-3β in OM, IM and matrix. Exposing cells to reactive oxygen species (ROS) by using antimycin A increased
the levels of DUSP5 and PHLPP-1 mainly in OM and induced dephosphorylation of Akt, ERK and GSK-3β. The
mitochondrial localization of DUSP5 was confirmed by experiments with mitochondria purified by Percoll
gradient centrifugation and by transfection of cells with GFP-tagged DUSP5. Knockdown of either DUSP5 or
PHLPP-1 increased the levels of both Thr202/Tyr204-phospho-ERK and Ser473-phospho-Akt in mitochondria.
Cell death induced by antimycin A was suppressed by siRNA-mediated knockdown of DUSP5. The results suggest
that Akt and ERK in mitochondria show distinct intra-mitochondrial localization and crosstalk in GSK-3β reg-
ulation and that recruitment of DUSP5 as well as PHLPP-1 to mitochondria contributes to ROS-induced termi-
nation of the protective signaling.
1. Introduction
More than 20 protein kinases have been reported to localize in
mitochondria and to be involved in the regulation of metabolism, redox
signaling, mitochondrial fission/fusion, mitophagy and cell death/sur-
vival [1–3]. Of the kinases in mitochondria, glycogen synthase kinase 3-
β (GSK-3β) plays a major role in regulation of cell sensitivity to necrosis
[4–6]. A major mechanism of cell necrosis is irreversible opening of the
mitochondrial permeability transition pore (mPTP), the megachannel
forming a complex in the mitochondrial inner membrane (IM), in re-
sponse to various stresses. Opening of the mPTP is triggered by reactive
oxygen species (ROS) and Ca2+ overload, and the threshold for mPTP
opening is regulated by metabolic factors and pro- and anti-survival
signal pathways [5,7]. An interesting feature of the pro-survival path-
ways targeting the mPTP is convergence of signals mediated by extra-
cellular signal-regulated kinases (ERK), Akt and protein kinase C-ε
(PKC-ε) to GSK-3β [4–6]. Previous studies from this laboratory have
shown that GSK-3β physically interacts with regulatory subunits of the
mPTP complex and that the threshold for mPTP opening is elevated
when GSK-3β is inactivated by phosphorylation at Ser9 [5,6,8]. It has
been shown that there is a causal relationship between inactivation of
GSK-3β and protection from ischemia/reperfusion injury in the heart,
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kidney and brain in vivo [5,6,8–11]. However, how the activity of GSK-
3β interacting with the mPTP complex is regulated by its upstream
protein kinase has not been fully elucidated, while Akt, ERK, PKC-ε as
well as GSK-3β are known to localize in mitochondria [5,6,12,13].
Several protein phosphatases including MKP-1, PTEN-L, PP1, and
PP2A have also been reported to localize in mitochondria and to play
roles in the regulation of phosphoproteins in the mitochondrial outer
membrane (OM) [1–3]. However, protein phosphatases that are in-
volved in termination of intra-mitochondrial signaling mediated by Akt,
ERK and PKC-ε have not been fully characterized. Gao et al. [14] re-
ported that PH domain leucine-rich repeat protein phosphatase-1
(PHLPP-1) selectively dephosphorylates Akt at Ser473 in tumor cells.
Miyamoto et al. [15] recently showed that PHLPP-1 resides in mi-
tochondria in cardiomyocytes and that Ser473-phosphorylation of Akt
in mitochondria by leukemia inhibitory factor or insulin-like growth
factor-1 (IGF-1) was significantly potentiated by PHLPP-1 knockdown.
On the other hand, a protein phosphatase involved in depho-
sphorylation of ERK in mitochondria has not been identified.
In the present study, to obtain insight into the mechanism by which
the activity of GSK-3β interacting with the mPTP complex is regulated,
we examined intra-mitochondrial localization of pro-survival kinases
upstream of GSK-3β in a baseline condition and their responses to ac-
tivation of pro-survival signal pathways and to oxidant stress. IGF-1 was
selected since this ligand is capable of protecting different types of cells,
including cardiomyocytes and renal tubular cells, from oxidant stress-
induced cell death [16–19] and reportedly induces Akt translocation to
mitochondria [20]. We also examined the hypothesis that PHLPP-1 and
dual specificity MAPK phosphatase 5 (DUSP5) play major roles in the
regulation of mitochondrial Akt and ERK. The rationale for this hy-
pothesis is three-fold. First, involvement of PHLPP-1 in the regulation of
mitochondrial Akt was suggested in two earlier reports [14,15] as
mentioned above. Second, DUSP5 specifically dephosphorylates ERK
[21,22], and the probability of the N-terminal amino acid sequence of
DUSP5 functioning as a mitochondria-targeting sequence (MTS) is
moderate according to MitoProt II, an MTS-predicting algorithm [23],
although DUSP5 has been reported to localize only in nuclei
[21,24,25]. Third, immunostaining of mouse embryonic fibroblasts
transfected with DUSP5-Myc in a study by Kidger et al. [26] showed
perinuclear dot-like staining, which could have been signals of DUSP5
in mitochondria.
2. Materials and methods
2.1. Drug treatment protocols
H9c2 and HEK293 cells were cultured in DMEM supplemented with
10% FBS, and the medium was changed to serum-free medium 24 h
prior to commencement of drug treatment. For activation of pro-sur-
vival kinases, cells were treated with IGF-1 (50 nmol/L, 791-MG, R & D
Systems) for 45 min before mitochondrial isolation or LDH assay.
Antimycin A, a mitochondrial complex III inhibitor, was used for in-
duction of cell death as in previous studies [8,16,27,28]. Cells were
treated with antimycin A (100 μmol/L, A8674, Sigma-Aldrich) for
30 min with or without co-treatment with IGF-1 before mitochondrial
isolation or LDH assay (i.e., antimycin A was added at 15 min after
commencing IGF-1 treatment). For scavenging ROS in mitochondria,
treatment with triphenylphosphonium chloride (mito-TEMPO,
SML0737, Sigma-Aldrich), a mitochondria-targeted ROS scavenger, was
commenced 15 min prior to the treatment with antimycin A and con-
tinued until cell harvest (i.e., cells were treated with mito-TEMPO for
45 min before mitochondrial isolation.).
2.2. Mitochondrial isolation and sub-mitochondrial fractionation by trypsin
digestion
Mitochondrial fractions were prepared by using a mitochondrial
isolation kit (Pierce) according to the manufacturer's protocol. To de-
termine proteins in sub-mitochondrial compartments, samples of mi-
tochondria stepwisely digested with trypsin were prepared. Isolated
mitochondria (50 μg) were incubated with trypsin at concentrations of
1–10,000 μg/mL (T1426, Sigma-Aldrich) in an assay buffer (250 mmol/
L sucrose, 10 mmol/L EGTA/Tris, 10 mmol/L Tris-HCl) for 60 min at
4 °C. After addition of 10 μL of trypsin inhibitor soybean (M191,
Amresco) and 10 μL of protease inhibitor cocktail (87786, Thermo
Fisher Scientific) to the assay buffer, the mitochondria were collected
and then centrifuged twice at 18,000 g for 10 min. Then the pellet was
centrifuged twice in the assay buffer at 18,000 g for 5 min each time
and prepared for immunoblotting in sample buffer (T1165, Sigma-
Aldrich).
2.3. Mitochondrial purification by Percoll gradient centrifugation
Mitochondrial purification by Percoll gradient centrifugation was
performed as described previously [29] with slight modification.
Briefly, mitochondria isolated from HEK293 cells were suspended in
200 μL of isolation buffer (250 mmol/L sucrose, 10 mmol/L HEPES,
1 mmol/L EGTA, protease inhibitor and phosphatase inhibitor cock-
tail), put on the top of 6 mL of 30% Percoll solution diluted in isolation
buffer, and then centrifuged at 35,000 g for 30 min using a swing-type
rotor. Of the two layers observed after centrifugation, the upper layer
containing debris was discarded and the lower layer was collected and
centrifuged twice at 10,300 g for 10 min each time. The pellet con-
taining purified mitochondria was used for immunoblotting.
2.4. Transfection of siRNA for PKC-ε, DUSP5 and PHLPP-1
Transfection of siRNA was performed using siRNA (Sigma-Aldrich)
against PKC-ε (sense: 5′-GUCAUCUACAGGGAUUUGATT-3′, anti-sense:
5′-UCAAAUCCCUGUAGAUGACTT-3′), DUSP5 (sense: 5′-CAGUUGAAA
UCCUUCCCUUTT-3′, anti-sense: 5′-AAGGGAAGGAUUUCAACUGTT-3′)
and PHLPP-1 (sense: 5′-GAGACAAUAAGCUUGGUGATT-3′, anti-sense:
5′-UCACCAAGCUUAUUGUCUCTT-3′) with Lipofectamine™ RNAiMAX
(LMRNA015, Thermo Fisher Scientific) following the manufacturer's
protocol.
2.5. Immunoblotting
Immunoblotting was performed as reported previously [8,16]. The
antibodies used were rabbit polyclonal anti-Akt (9272, Cell Signaling
Technology), rabbit polyclonal anti-phospho-Akt (Ser473) (9271, Cell
Signaling Technology), goat polyclonal anti-ANT1/2 (N-19, Santa Cruz
Biotechnology), rabbit polyclonal anti-COX IV (ab16056, Abcam),
mouse monoclonal anti-cyclophilin D (AP1035, Calbiochem), rabbit
monoclonal anti-DUSP5 (ab200708, Abcam), rabbit polyclonal anti-
p44/42 MAPK (ERK1/2) (9102, Cell Signaling Technology), rabbit
polyclonal anti-phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204)
(9101, Cell Signaling Technology), rabbit monoclonal anti-GSK-3β
(9315, Cell Signaling Technology), rabbit monoclonal anti-phospho-
GSK-3β (Ser-9) (9322, Cell Signaling Technology), rabbit polyclonal
anti-histone H3 (ab1791, Abcam), rabbit polyclonal anti-lamin A/C
(2032, Cell Signaling Technology), rabbit polyclonal anti-PHLPP-1 (07-
1341, Millipore), mouse monoclonal anti-PKC-ε (610086, BD Trans-
duction Laboratories), rabbit polyclonal anti-phospho-PKC-ε (Ser729)
(06-821, Millipore), mouse monoclonal anti-prohibitin (sc-56346,
Santa Cruz Biotechnology), and rabbit polyclonal anti-TOMM20 (sc-
11415, Santa Cruz Biotechnology). The FUSION Solo S system (Vilber
Lourmat, France) was used for obtaining immunoblotting images, and
proteins were quantified by measuring intensities of individual bands
by Image J software (National Institutes of Health).
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2.6. mRNA quantification
Total RNA was isolated from cells by using a RNeasy Mini Kit
(74106, Qiagen, Valencia, CA, USA). First-strand cDNA was synthesized
using High-Capacity cDNA Reverse Transcription Kit (4374966,
Applied Biosystems). DNA amplification was performed in ABI/
PRISM7500 (Applied Biosystems, Inc., Thermo Fisher Scientific) by
using Taqman Universal Master Mix (4305719, Applied Biosystems,
Inc., Thermo Fisher Scientific). The following Taqman probes (Applied
Biosystems, Inc., Thermo Fisher Scientific) were used: for human AKT1
(Hs00178289_m1), MAPK3 (Hs00385075_m1), MAPK1
(Hs01046830_m1), GSK-3B (Hs01047719_m1), DUSP5
(Hs00244839_m1), PHLPP-1 (Hs01597875_m1) and ACTB
(Hs99999903_m1). All assays were performed in duplicate and by the
standard curve method using serial cDNA dilution.
2.7. Fluorescence microscopy analysis
H9c2 cells cultured on collagen-coated glass dishes were transfected
with green fluorescent protein (GFP)-tagged DUSP5 (RG209128,
OriGene) by use of FuGENE HD (E2312, Promega) following the
manufacturer's instructions. Two days after transfection, the cells were
stained with MitoTracker Red (M22425, Thermo Fisher Scientific) for
15 min and fixed with 4% paraformaldehyde. The cells were then wa-
shed with PBS and examined by confocal laser scanning microscopy
(LSM 510-ZEN 2009, Carl Zeiss Co.).
2.8. Cell death assay
The LDH activity of the culture medium was assayed with
CytoTox96 (G1780, Promega) according to the manufacturer's protocol.
LDH activity in the medium as a percentage of total cellular LDH ac-
tivity in the well was used as an index of cell necrosis.
2.9. Statistical analysis
Group mean data are shown as means ± S.E. One-way analysis of
variance was used to test differences among group mean data. When
analysis of variance indicated a significant overall difference, multiple
comparisons were performed using the Student-Newman-Keul post hoc
test. The difference was considered to be statistically significant if p
was<0.05. In immunoblotting experiments, 6–8 samples were used for
each treatment group (see the number in figure legends), and each
sample was duplicated in mRNA quantification.
3. Results
3.1. Step-wise mitochondrial digestion by trypsin for analysis of intra-
mitochondrial localization of proteins
Using HEK293 and H9c2 cells, we performed sub-mitochondrial
fractionation by incubating isolated mitochondria in trypsin at different
concentrations (1–10,000 μg/mL), which step-wisely digested mi-
tochondria from the OM to the IM and to the matrix (Figs. 1A and S1).
Without incubation in trypsin, distinct bands of TOMM20, prohibitin
and cyclophilin D, marker proteins localizing in the OM, IM and matrix,
respectively, were observed by immunoblotting analyses (Fig. S2A, lane
for 0 μg/mL). The band for TOMM20 almost disappeared after in-
cubation in 1 μg/mL of trypsin and was no longer detected when the
mitochondria were incubated in trypsin at a concentration of 10 μg/mL
or higher (Fig. S2A), indicating that most of the OM protein was di-
gested by 1 μg/mL of trypsin. Similarly, it was indicated that total di-
gestion of the IM protein was achieved by 1000 μg/mL of trypsin, since
the density of bands for prohibitin was completely undetectable at
1000 μg/mL or higher. The effect of 1000 μg/mL of trypsin on the band
density of cyclophilin D was modest, suggesting that matrix proteins
were preserved under the condition of treatment with 1000 μg/mL of
trypsin. Based on these findings, we used the difference between im-
munoblot density of a protein in mitochondria without trypsin diges-
tion and the density in mitochondria digested with 1 μg/mL of trypsin
as an index for amount of the protein in the OM. Similarly, the amount
of a protein in the IM was estimated as the difference between the
immunoblot density in mitochondria digested with 1 μg/mL of trypsin
and the density in mitochondria digested with 1000 μg/mL of trypsin.
Residual proteins after digestion with trypsin at 1000 μg/mL were in-
terpreted to be localized in the matrix (Fig. S2B).
3.2. Translocation of pro-survival kinases to mitochondria in response to
IGF-1
Immunoblot signals for Akt, ERK and GSK-3β were detected in the
total mitochondrial fraction harvested from vehicle-treated HEK293
and H9c2 cells as shown in Figs. 1A and S1. Treatment with IGF-1 in-
duced mitochondrial translocation of Akt, ERK and GSK-3β and in-
creased levels of phosphorylation of all of the three kinases (Fig. 1B).
Since PKC-ε in mitochondria reportedly participates in cell protec-
tion against ischemia/reperfusion injury [5,30], we examined the re-
sponse of this kinase to IGF-1 treatment. However, unlike Akt and ERK,
PKC-ε was not translocated to the mitochondria by IGF-1 (Fig. S4A).
IGF-1 treatment increased the level of phospho-PKC-ε in the cytosol but
not in mitochondria (Fig. S4B). Specificity of the PKC-ε signal in im-
munoblotting was confirmed by PKC-ε-siRNA and a PKC activator,
phorbol 12-myristate 13-acetate (data not shown).
3.3. Effects of oxidant stress on pro-survival kinase levels in mitochondria
Oxidant stress induced by antimycin A significantly reduced Akt in
mitochondria while it conversely increased ERK and GSK-3β (Fig. 1A
and B). The finding for GSK-3β is consistent with the results of our
previous study showing that ROS induced translocation of GSK-3β to
mitochondria by a VDAC2-dependent mechanism [8] and with the re-
sults of a study by Galli et al. [31] showing that hydrogen peroxide
promoted ERK translocation to mitochondria. Since the mRNA level of
Akt1, MAPK1+MAPK3 (ERK) or GSK-3β was not affected by antimycin
A (Fig. S3), the changes in the protein levels caused by antimycin A
were unlikely to be mediated by altered expression of the kinases.
While responses of protein levels of Akt, ERK and GSK-3β to antimycin
A treatment were different, their levels of phosphorylation were simi-
larly reduced (Fig. 1A and B), indicating turning off of pro-survival
signals mediated by the protein kinases in mitochondria.
3.4. Intra-mitochondrial localization of pro-survival kinases and their
responses to IGF receptor activation and oxidant stress
Levels of protein kinases in each intramitochondrial compartment
with or without IGF-1 and/or antimycin A treatment are shown in
Fig. 1C. Akt was localized at comparable levels in the OM, IM and
matrix under the baseline condition. ERK and GSK-3β levels were
higher in the OM than in the IM or matrix, though the difference in ERK
level did not reach statistical significance.
IGF-1 induced Akt translocation preferentially to the matrix,
whereas it increased ERK and GSK-3β predominantly in the OM.
Phospho-Akt levels in all mitochondrial compartments were elevated by
IGF-1, while the increase in the phospho-ERK level was significant in
the IM and matrix but not in the OM. The levels of phospho-GSK-3β
were significantly elevated after IGF-1 treatment in all mitochondrial
compartments. GSK-3β is a substrate of both Akt and ERK [4,5], and
Ser9-phospho-GSK-3β interacts with regulatory subunits of the mPTP in
the IM and matrix to inhibit its opening [5,8]. Thus, the results shown
in Fig. 1C support the notion that phosphorylation of GSK-3β inter-
acting with the mPTP subunits is achieved by ERK in the IM and by both
ERK and Akt in the matrix, while GSK-3β in the OM is phosphorylated
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Fig. 1. Mitochondrial translocation and sub-
mitochondrial distribution of mitochondrial
protective kinases in response to treatment
with IGF-1 and/or antimycin A in HEK293
cells.
Cells were treated with a vehicle or IGF-1
(50 nmol/L) for 45 min with or without
additional treatment with antimycin A
(100 μmol/L) for 30 min before isolation of
mitochondria.
(A) Representative immunoblotting for Akt,
Ser473-phospho-Akt, ERK, Thr202/Tyr204-
phospho-ERK, GSK-3β, Ser9-phospho-GSK-
3β, TOMM20, prohibitin, COX IV and cy-
clophilin D. (B) Densitometric analyses for
protein levels of Akt, Ser473-phospho-Akt,
ERK, Thr202/Tyr204-phospho-ERK, GSK-3β
and Ser9-phospho-GSK-3β normalized by
COX IV in total mitochondria. The mi-
tochondria were harvested from cells
treated with a vehicle, IGF-1, antimycin A
and IGF-1+antimycin A. N = 8 in each
group. (C) Densitometric analyses for the
levels of the same proteins as those in A in
the OM, IM and matrix of the mitochondria.
N = 8 in each group.
TOMM20, translocase of outer mitochon-
drial membrane 20. COX IV, cytochrome c
oxidase subunit 4. CyPD, cyclophilin D. AA,
antimycin A. IGF-1, insulin-like growth
factor-1. OM, mitochondrial outer mem-
brane. IM, mitochondrial inner membrane.
*, p < 0.05.
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by Akt, possibly before its transportation to the IM. Treatment with
antimycin A dephosphorylated Akt, ERK and GSK-3β similarly in the
OM, IM and matrix.
3.5. Effects of IGF-1 on modification of pro-survival kinases by oxidative
stress
Pretreatment with IGF-1 did not affect antimycin A-induced trans-
location of ERK and GSK-3β, but it partly preserved phospho-Akt and
phospho-GSK-3β levels (Fig. 1B) presumably by elevation of phos-
phorylation levels of the kinases before antimycin A treatment. The
Fig. 2. Mitochondrial translocation of protective ki-
nases in response to treatment with antimycin A
and/or mito-TEMPO in HEK293 cells.
(A) Representative immunoblotting for Akt, Ser473-
phospho-Akt, ERK, Thr202/Tyr204-phospho-ERK,
GSK-3β, Ser9-phospho-GSK-3β, and COX IV with or
without treatment with antimycin A and/or mito-
TEMPO in mitochondria from HEK293 cells.
(B) Densitometric analyses for protein levels of Akt,
Ser473-phospho-Akt, ERK, Thr202/Tyr204-phospho-
ERK, GSK-3β and Ser9-phospho-GSK-3β normalized
by COX IV in total mitochondria. The mitochondria
were harvested from cells treated with antimycin A
and/or mito-TEMPO as labeled. N = 6 in each
group.
COX IV, cytochrome c oxidase subunit 4. AA, anti-
mycin A. mito-TEMPO, triphenylphosphonium
chloride. *, p < 0.05.
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effects of IGF-1 on Akt and GSK-3β phosphorylation appeared to be
present in all mitochondrial compartments (Fig. 1C).
3.6. Effects of a mitochondria-targeted ROS scavenger on responses of pro-
survival kinases to oxidative stress
To confirm that the effects of antimycin A on mitochondrial pro-
survival kinases were mediated by ROS, we examined whether co-
treatment with a mitochondria-targeted ROS scavenger, mito-TEMPO
(1 μmol/L, for 90 min) [32,33], attenuates the effects of antimycin A.
mito-TEMPO cancelled the antimycin A-induced changes in protein
levels of Akt, ERK and GSK-3β in mitochondria, while mito-TEMPO
alone did not affect the protein levels of the mitochondrial kinases
(Fig. 2A and B). The results confirmed involvement of ROS in translo-
cation of ERK [31] and GSK-3β [8] to the mitochondria and also suggest
that ROS modify Akt translocation to or from the mitochondria and/or
Akt protein turnover. Importantly, mito-TEMPO partly prevented de-
phosphorylation of Akt, ERK and GSK-3β after antimycin A treatment,
suggesting that ROS were involved in dephosphorylation of the kinases.
3.7. Mitochondrial localization of PHLPP-1
Confirming an earlier report [15], we could detect PHLPP-1 in mi-
tochondria (Fig. 3A and B). Treatment with IGF-1 or antimycin A in-
duced translocation of PHLPP-1 to mitochondria, where it localized
mainly in the OM (Fig. 3B and C). The effect of IGF-1 possibly reflects a
negative feedback mechanism that operates to avoid unlimited phos-
phorylation of mitochondrial Akt. The PHLPP-1 mRNA level was un-
changed by IGF-1 but was increased by antimycin A (Fig. S5). In-
volvement of ROS in antimycin A-induced translocation of PHLPP-1 to
mitochondria was confirmed by the findings that mito-TEMPO atte-
nuated translocation of PHLPP-1 by antimycin A (Fig. 3D). The effect of
IGF-1 on PHLPP-1 level in mitochondria was abolished by co-treatment
with antimycin A, suggesting that PHLPP-1 translocation by IGF-1 is
sensitive to ROS.
3.8. Mitochondrial localization of DUSP5
We detected immunoblot signals for DUSP5 in mitochondria
(Fig. 3A and B), residing exclusively in the OM (Fig. 3C). IGF-1 or an-
timycin A increased DUSP5 recruited to the mitochondria pre-
dominantly in the OM (Fig. 3B and C). Neither IGF-1 nor antimycin A
significantly changed the DUSP5 mRNA expression level (Fig. S5). The
effect of antimycin A was significantly inhibited by mito-TEMPO
(Fig. 3D), indicating involvement of ROS in DUSP5 translocation to
mitochondria. The effect of IGF-1 on DUSP5 level in mitochondria was
lost by antimycin A (Fig. 3A), suggesting that IGF-1-induced translo-
cation of DUSP5 is sensitive to ROS as in the case of PHLPP-1.
To exclude the possibility that mitochondrial DUSP5 in the im-
munoblotting experiments were artefacts due to contamination of nu-
clear proteins in mitochondrial fractions, we examined the presence of
DUSP5 in mitochondria that were isolated by different centrifugation
protocols. Our initial protocol to isolate mitochondria (centrifugation at
700 g for 10 min, twice) yielded reasonably pure mitochondria as de-
monstrated by detection of only negligible bands for histone H3, a
nuclear protein, on immunoblotting (Fig. 4A). Although a single 30-min
centrifugation procedure resulted in increased contamination of nuclear
protein, we were able to enhance the purity of mitochondria by in-
creasing the number of 10 min-centrifugations to 3 times, since almost
no histone H3 band was detected in the mitochondrial fraction obtained
by the protocol. Even in that mitochondrial fraction, a clear band was
recognized by a DUSP5 antibody. We confirmed that the DUSP5 anti-
body recognized the right proteins by results showing that knockdown
of DUSP5 by siRNA substantially reduced the intensities of the bands
detected by the antibody in whole cell homogenates (Fig. S6). To ex-
clude the possibility of histone H3 protein being contaminated at a level
below the threshold for detection by immunoblotting, we further pur-
ified mitochondria by Percoll gradient centrifugation. After successful
separation of pure mitochondria from crude mitochondria by Percoll
gradient centrifugation (Fig. S7), the purified mitochondria were col-
lected and subjected to immunoblotting. DUSP5 was detected in the
Percoll gradient centrifugation-purified mitochondria as well as in the
nuclei and crude mitochondria (Fig. 4B). Furthermore, transfection of
GFP-tagged DUSP5 in H9c2 cells demonstrated that GFP-DUSP5 is co-
localized with mitochondria stained by MitoTracker red in addition to
its localization in the nucleus (Fig. 4C).
3.9. Functional relationships between DUSP5, PHLPP-1 and pro-survival
kinases in mitochondria
To examine the roles of PHLPP-1 and DUSP5 in dephosphorylation
of Akt and ERK in mitochondria, mitochondrial fractions were collected
from cells 48 h after transfection with PHLPP-1-siRNA, DUSP5-siRNA or
control-siRNA. Transfection of the siRNAs reduced the expression of
PHLPP-1 and DUSP5 by 46% and 28%, respectively, in the mitochon-
drial fractions (Fig. S8). As expected, siRNA-mediated knockdown of
PHLPP-1 increased the phosphorylation of Akt at Ser473 in mitochon-
dria in cells treated with either a vehicle or antimycin A (Fig. 5A and B).
Knockdown of PHLPP-1 did not further increase the phospho-Akt level
in IGF-1-treated cells, suggesting that the level of phospho-Akt in mi-
tochondria is limited to a certain level by a mechanism other than
PHLPP-1. Unexpectedly, the level of ERK phosphorylation at Thr202/
Tyr204 in mitochondria was also increased by knockdown of PHLPP-1
in cells treated with a vehicle or antimycin A. This finding indicates
crosstalk between Akt- and ERK-mediated signaling in mitochondria. As
expected from the increased phosphorylation of Akt and ERK being
upstream of GSK-3β, GSK-3β phosphorylation was also significantly
increased by knockdown of PHLPP-1. Similar to knockdown of PHLPP-
1, knockdown of DUSP5 induced not only phosphorylation of ERK but
also phosphorylation of Akt and GSK-3β in mitochondria, and DUSP5
knockdown had no additive effect on IGF-1-induced phosphorylation of
ERK (Fig. 5C and D).
Total protein levels of ERK and Akt were not significantly changed
by reduction of DUSP5 or PHLPP-1 level (Fig. 5A and C, densitometry
data not shown). Thus, it is likely that changes in phospho-ERK and
phospho-Akt levels by PHLPP-1-siRNA and by DUSP5-siRNA were in-
duced by their phosphorylation in mitochondria, not by translocation of
phosphorylated forms of the kinases.
Fig. 3. Mitochondrial translocation and sub-mitochondrial distribution of phosphatases in response to treatment with IGF-1 and/or antimycin A.
(A) Representative immunoblotting for PHLPP-1, DUSP5, TOMM20, prohibitin and cyclophilin D in HEK293 cells. (B) Densitometric analyses for protein levels of
PHLPP-1 and DUSP5 normalized by COX IV in total mitochondria. The mitochondria were harvested from cells treated with a vehicle, IGF-1, antimycin A or IGF-
1+antimycin A. N = 8 in each group. (C) Densitometric analyses for protein levels of PHLPP-1 and DUSP5 normalized by COX IV in the OM and IM. Note that the
phosphatases were not detected in the matrix. N = 8 in each group. (D) Representative immunoblotting and results of densitometric analyses for protein levels of
PHLPP-1 and DUSP5 normalized by COX IV in total mitochondria. N = 6 in each group. Mitochondria were harvested from cells treated with antimycin A and/or
mito-TEMPO as labeled.
PHLPP-1, PH domain leucine-rich repeat protein phosphatase-1. DUSP5, dual-specificity phosphatase 5. COX IV, cytochrome c oxidase subunit 4. IGF-1, insulin-like
growth factor-1. AA, antimycin A. OM, mitochondrial outer membrane. IM, mitochondrial inner membrane. a.u., arbitrary unit. *, p < 0.05.
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3.10. Role of DUSP5 in regulation of protective signals against oxidative
stress-induced cell death
To confirm that DUSP5 contributes to ROS-induced cell death by
dephosphorylation of ERK and Akt in mitochondria, we examined the
effect of DUSP5 knockdown on cell necrosis induced by antimycin A.
LDH release into the culture medium was used as an index of cell ne-
crosis as in previous studies [8,16,28]. Treatment with antimycin A
increased LDH release by 3.0 fold, and IGF-1 and DUSP5 knockdown
suppressed the antimycin A-induced LDH release by 25.7% and by
25.9%, respectively (Fig. 6). DUSP5 knockdown did not afford further
protection in IGF-1-treated cells, as expected from the findings that
levels of phosphorylated GSK-3β were similar in cells treated with IGF-1
and those treated with IGF-1 and DUSP5 siRNA (Fig. 5D).
4. Discussion
GSK-3β has multiple functions in cells, which are enabled by post-
translational modification, translocation to intracellular organelles and
presence of priming kinases for substrates [34,35]. One of the major
functions of GSK-3β in mitochondria is regulation of the threshold for
mPTP opening [4,6,8,35]. The mPTP is a physiologically closed
megachannel in the IM, and its irreversible opening triggered by ROS
and Ca2+ overload results in collapse of the mitochondrial membrane
potential, leading to necrotic cell death. The current model of the mPTP
complex consists of a dimer of F1F0-ATPase forming a channel and
regulatory subunits in the IM and matrix [36,37]. Several lines of evi-
dence indicate that GSK-3β regulates the threshold for mPTP opening
by its direct interaction with subunits of the mPTP complex. Our pre-
vious studies showed that oxidant stress induces GSK-3β translocation
in a kinase activity- and VDAC2-dependent manner to mitochondria,
where GSK-3β interacts with cyclophilin D, and lowers the threshold for
mPTP opening [8,28,38]. Interaction of phospho-Ser9-GSK-3β with
adenine nuclotide translocator, a subunit of the mPTP in the IM, was
observed in the myocardium that became resistant to ischemia/re-
perfusion injury by preconditioning and erythropoietin receptor acti-
vation [39]. Furthermore, the level of GSK-3β phosphorylation in mi-
tochondria was closely correlated with the threshold for mPTP opening
[4,38]. However, how GSK-3β, which interacts with the mPTP, is
regulated in mitochondria has not been clarified. As a first step to ad-
dress this issue, we aimed to characterize intra-mitochondrial locali-
zation of Akt and ERK, upstream kinases of GSK-3β, and their responses
to activation of IGF receptors coupling with GSK-3β signaling. The
pattern of changes in the protein kinases in response to IGF-1 treatment
(Fig. 1) support the notion that there are redundant mechanisms of
phosphorylation for GSK-3β interacting with multiple subunits of the
mPTP complex: phosphorylation by ERK in the IM and phosphorylation
by both ERK and Akt in the matrix.
In addition to GSK-3β in the IM and matrix where subunits of the
mPTP complex reside, GSK-3β in the OM was phosphorylated together
with Akt by IGF receptor activation. The biological implication of GSK-
3β phosphorylation in the OM is unclear. However, a few speculations
Fig. 4. Confirmation of the presence of DUSP5 in mitochondria.
(A) Representative immunoblotting for DUSP5, histone H3 and COX IV in whole cell lysates, nuclear fraction, mitochondrial fraction and cytosolic fraction.
Mitochondrial fractions were obtained by repeated centrifugation for various periods and various numbers of times as indicated. Three separate experiments showed
similar results. (B) Immunoblotting for DUSP5, GSK-3β, COX IV, lamin and α-tubulin in whole cell lysates, nuclear fraction, purified mitochondrial fraction obtained
by Percoll-gradient centrifugation, crude mitochondrial fraction obtained by repeated centrifugation and cytosolic fraction. COX IV, lamin and α-tubulin serve as
marker proteins for the mitochondria, nuclei and cytosol, respectively. (C) Representative fluorescence images of H9c2 cells transfected with GFP-tagged DUSP5 and
stained with MitoTracker Red. GFP-DUSP5, green fluorescent protein-tagged DUSP5.
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are possible: the formation of a reservoir of phospho-GSK-3β to be
transported to the IM, inactivation of GSK-3β in the mitochondria-as-
sociated ER membrane, which would suppress mitochondrial Ca2+
overload [40], and inhibition of mitochondrial fission mediated by
GSK-3β-mediated DRIP1-Ser616-phosphorylation [41,42]. These spec-
ulations remain to be examined.
The detrimental effect of ROS on the mPTP is thought to be medi-
ated by their direct effects on protein subunits of the mPTP and in-
duction of interaction of the mPTP with non-phosphorylated GSK-3β
[5,7,8]. The present study showed an additional mechanism by which
ROS lower the threshold for mPTP opening. Antimycin A treatment
induced translocation of PHLPP-1 and DUSP5 to mitochondria together
with marked dephosphorylation of Akt, ERK and GSK-3β in mi-
tochondria (Figs. 1 and 3). The contribution of ROS in the PHLPP-1 and
DUSP5 translocation was confirmed by mito-TEMPO (Fig. 3), and in-
volvement of PHLPP-1 and DUSP5 in ROS-induced dephosphorylation
of the kinases was confirmed by the effects of PHLPP-1 and DUSP5
knockdown (Fig. 5). Taken together, the findings indicate that ROS-
induced translocation of PHLPP-1 and DUSP5 mediates, at least partly,
the switching off of cytoprotective Akt/ERK-GSK-3β signaling in mi-
tochondria.
How DUSP5 translocates to mitochondria in response to ROS re-
mains unclear, but there is a possibility that the N-terminus of DUSP5
functions as an MTS. MTSs consist of 15–40 N-terminal amino acid
residues dotted with a few positively charged amino acid residues, ar-
ginine (R) or lysine (K) [43], by which nucleus-encoded mitochondrial
proteins are directed to mitochondria [43,44]. MitoProt II [23] predicts
that the N-terminus of human DUSP5 (MKVTSLDGRQLRKMLRKEAA-
ARCVVLDCRPYLAFAASNVR) may function as an MTS. Another possi-
bility is that DUSP5, ERK and other scaffold proteins form a signaling
complex that is transported to mitochondria altogether as reported for a
signaling complex consisting of DUSP16 and MKK7 [45,46]. Interest-
ingly, DUSP5 and PHLPP-1 localized mostly in the OM both in a
baseline condition and after additional translocation in response to
ROS. The localization might reflect functions of the phosphatases to
control levels of phosphorylation in Akt and ERK at the entry into mi-
tochondrial compartments.
Knockdown of DUSP5 or PHLPP-1 expression similarly increased
Fig. 5. Crosstalk between ERK signaling and Akt signaling in mitochondria.
(A) Representative immunoblotting for PHLPP-1, total Akt, Ser473-phospho-Akt, total ERK, Thr202/Tyr204-phospho-ERK, total GSK-3β, Ser9-phospho-GSK-3β, and
COX IV in mitochondria. (B) Densitometric analyses for the levels of the Ser473-phospho Akt, Thr202/Tyr204-phospho-ERK and Ser9-phospho-GSK-3β normalized
by COX IV in total mitochondria. N = 7 in each group. (C) Representative immunoblotting for DUSP5 and total and phosphorylated protective kinases in mi-
tochondria as in A. (D) Densitometric analyses for the levels of phosphorylated kinases as in B. The levels of phospho-Akt and phospho-ERK are also shown in graphs
with smaller vertical axis scales in a dashed square box for the differences to be clearly visible. N = 7 in each group. Mitochondria were harvested from HEK293 cells
treated with IGF-1 or antimycin A 48 h after transfection with control-siRNA or PHLPP-1-siRNA.
PHLPP-1, PH domain leucine-rich repeat protein phosphatase-1. DUSP5, dual-specificity phosphatase 5. COX IV, cytochrome c oxidase subunit 4. IGF-1, insulin-like
growth factor-1. AA, antimycin A. a.u., arbitrary unit. *, p < 0.05.
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phosphorylation of both ERK and Akt in mitochondria (Fig. 5), in-
dicating crosstalk between mitochondrial ERK- and Akt-mediated sig-
naling. Earlier studies using whole cells showed that there is crosstalk
between the PI3K/Akt signal pathway and the MEK/ERK signal
pathway: cross-activation and cross-inhibition between PI3K/Akt/TSC/
mTORC1 signaling and Ras/Raf/MEK/ERK signaling [47]. Un-
fortunately, reports regarding intra-mitochondrial localization of signal
molecules upstream of Akt and ER such as PDK1, mTORC2, and MEK
are limited in the literature [48–50]. Further investigation is necessary
to clarify how ERK- and Akt-mediated signaling pathways crosstalk in
mitochondria.
In conclusion, there are distinct localizations of Akt, ERK and GSK-
3β in mitochondria, and mechanisms of Akt- and ERK-mediated phos-
phorylation for GSK-3β interacting with the mPTP complex appear re-
dundantly present in the IM and matrix (Fig. 7). DUSP5 as well as
PHLPP-1 are localized in the OM of mitochondria, and ROS-mediated
translocation of both phosphatases to mitochondria is associated with
inactivation of the mitochondrial pro-survival kinases. Furthermore,
mitochondrial DUSP5-ERK signaling and PHLPP-1-Akt signaling appear
to crosstalk in regulation of GSK-3β and thus regulation of the mPTP
opening threshold.
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Fig. 7. Proposed intra-mitochondrial localizations of pro-survival kinases upstream of GSK-3β interacting with the mPTP and protein phosphatases regulating Akt
and ERK.
Responses of the kinases and phosphatases to activation of pro-survival signal pathways by IGF-1 and to lethal oxidant stress are shown. PHLPP-1, PH domain
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tochondrial inner membrane. mPTP, mitochondrial permeability transition pore. IGF-1, insulin-like growth factor-1.
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